Clinical trial

A Study of IRESSA Treatment Beyond Progression in Addition to Chemotherapy Versus Chemotherapy Alone

NCT01544179

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2012-03-15

PhasePHASE3

Study timeline

Study start (actual)2012-03-15Date precision: day

Registry last updated2020-09-25

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Non-Small Cell Lung Cancerunresolved

Interventions

GefitinibDRUG · verified · RxNorm: gefitinib

PlaceboDRUG

PemetrexedDRUG · verified · RxNorm: pemetrexed

CisplatinDRUG · verified · RxNorm: cisplatin

Sponsors & collaborators

AstraZenecalead sponsor

Mapped research locations

BeijingChina6 SeoulSouth Korea2 BarcelonaSpain2 BudapestHungary2 ShanghaiChina2 RomaItaly2 GuangzhouChina2 ChengduChina2 MadridSpain1 ParisFrance1 TaipeiTaiwan1 Saint PetersburgRussia1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT01544179 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.